Real-world Treatment Patterns and Outcomes of Patients with Small Cell Lung Cancer Progressing after 2 Lines of Therapy

Approximately 234,030 new cases of lung cancer will be diagnosed in 2018, ~14% of which will be small cell lung cancer (SCLC) [1 –3]. SCLC is traditionally staged using the Veterans Affairs Lung Study Group staging system, which divides SCLC patients largely based on the size and spread of the tumor into 1 of 2 stages: limited-stage disease or extensive-stage (ES) disease [4–7]. SCLC presents with an aggressive clinical c ourse, frequently with widespread metastases at diagnosis and, as such, approximately two-thirds of patients have ES disease at diagnosis [8].

Source: Lung Cancer - November 8, 2018 Category: Cancer & Oncology Authors: Anna D. Coutinho, Manan Shah, Orsolya E. Lunacsek, Michael Eaddy, Joanne P. Willey Source Type: research